AI Article Synopsis

  • Dabrafenib plus trametinib shows strong effectiveness and manageable side effects for patients with -mutant glioma.
  • There is a notable case of a patient with recurrent anaplastic pleomorphic xanthoastrocytoma who had a complete and lasting response to this treatment.
  • Continued development of targeted therapies and treatment strategies is expected to enhance personalized care for high-grade glioma patients, ultimately improving their outcomes.

Article Abstract

Dabrafenib plus trametinib is a promising new therapy for patients affected by -mutant glioma, with high overall response and manageable toxicity. We described a complete and long-lasting response in a case of recurrent anaplastic pleomorphic xanthoastrocytoma CNS WHO-grade 3 mutated. Due to very poor prognosis, there are a few described cases of high-grade glioma (HGG) patients treated with the combined target therapy as third-line treatment. The emergence of optimized sequencing strategies and targeted agents, including multimodal and systemic therapy with dabrafenib plus trametinib, will continue to broaden personalized therapy in HGG improving patient outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11106409PMC
http://dx.doi.org/10.3389/fonc.2024.1359093DOI Listing

Publication Analysis

Top Keywords

dabrafenib trametinib
12
complete long-lasting
8
long-lasting response
8
high-grade glioma
8
case report
4
report complete
4
response multimodal
4
multimodal third
4
third treatment
4
treatment neurosurgical
4

Similar Publications

Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.

View Article and Find Full Text PDF

Sarcoidosis-Like Reaction in Melanoma Patients Receiving Immunotherapy or Targeted Therapy.

Case Rep Oncol Med

December 2024

Oncology Unit Fondazione, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

This case series highlights the complexity of sarcoidosis-like reactions (SLRs) during cancer treatment, specifically in patients receiving immunotherapy or targeted therapies for melanoma. SLRs can either mimic disease progression or present as part of the clinical manifestation, making diagnosis and treatment challenging. Our study reviewed the medical records of 31 patients who were candidates for postoperative treatment between June 2022 and June 2024.

View Article and Find Full Text PDF

A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with one to two-centimeter safety margins. For a correct stage classification and treatment decision, a sentinel lymph node biopsy shall be offered in patients with tumor thickness ≥ 1.

View Article and Find Full Text PDF

Thyroid cancer (TC) being the common endocrine malignancy is glooming steadily due to its poor prognosis. The treatment strategies of surgery, radiotherapy, and conventional chemotherapy are providing unsatisfactory output. However, combination therapy can negotiate the worse prognosis to the better, where chemoradiotherapy, radiotherapy with surgery, or dual chemotherapeutic drugs are being glorified.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!